1.Association As: 2018 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia 2018, 14(3):367–429.
2.Hebert LE, Weuve J, Scherr PA, Evans DA: Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 2013, 80(19):1778–1783.
3.Alzheimer’s Association: Changing the trajectory of Alzheimer’s disease: how a treatment by 2025 saves lives and dollars In.; 2015.
4.Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018:25708.
5.Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC: Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer’s & Dementia 2017, 13(8):841–849.
6.Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li Q-X, Martins R, Rowe C: High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 2018.
7.Mielke MM, Hagen CE, Xu J, Chai XY, Vemuri P, Lowe VJ, Airey DC, Knopman DS, Roberts RO, Machulda MM et al: Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers & Dementia 2018, 14(8):989–997.
8.Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D et al: Plasma beta-amyloid in Alzheimer’s disease and vascular disease. Sci Rep 2016, 6(26801):26801.
9.Bernick C, Zetterberg H, Shan G, Banks S, Blennow K: Longitudinal performance of plasma neurofilament light and tau in professional fighters: The Professional Fighters Brain Health Study. J Neurotrauma 2018, 35(20):2351–2356.
10.Mielke MM, Hagen CE, Wennberg AM, Airey DC, Savica R, Knopman DS, Machulda MM, Roberts RO, Jack CR, Petersen RC: Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging. Jama Neurol 2017, 74(9):1073–1080.
11.Piehl F, Kockum I, Khademi M, Blennow K, Lycke J, Zetterberg H, Olsson T: Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Multiple Sclerosis Journal 2017:1–9.
12.de Flon P, Laurell K, Sundström P, Blennow K, Söderström L, Zetterberg H, Gunnarsson M, Svenningsson A: Comparison of plasma and CSF Neurofilament light as outcome in a multiple sclerosis trial. 2018.
13.Rossi C, Angelucci A, Costantin L, Braschi C, Mazzantini M, Babbini F, Fabbri ME, Tessarollo L, Maffei L, Berardi N: Brain‐derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur J Neurosci 2006, 24(7):1850–1856.
14.Anderson MF, Åberg MA, Nilsson M, Eriksson PS: Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Developmental Brain Research 2002, 134(1–2):115–122.
15.Laske C, Stellos K, Hoffmann N, Stransky E, Straten G, Eschweiler GW, Leyhe T: Higher BDNF serum levels predict slower cognitive decline in Alzheimer’s disease patients. Int J Neuropsychopharmacol 2011, 14(3):399–404.
16.Dik MG, Pluijm SM, Jonker C, Deeg DJ, Lomecky MZ, Lips P: Insulin-like growth factor I (IGF-I) and cognitive decline in older persons. Neurobiol Aging 2003, 24(4):573–581.
17.Weinstein G, Beiser AS, Choi SH, Preis SR, Chen TC, Vorgas D, Au R, Pikula A, Wolf PA, DeStefano AL et al: Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. Jama Neurol 2014, 71(1):55–61.
18.Almeida O, Hankey G, Yeap B, Chubb SP, Gollege J, Flicker L: Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor-binding protein 3. Mol Psychiatry 2017:1–5.
19.Erickson KI, Prakash RS, Voss MW, Chaddock L, Heo S, McLaren M, Pence BD, Martin SA, Vieira VJ, Woods JA et al: Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci 2010, 30(15):5368–5375.
20.Nindl BC, Alemany JA, Rarick KR, Eagle SR, Darnell ME, Allison KF, Harman EA: Differential basal and exercise-induced IGF-I system responses to resistance vs. calisthenic-based military readiness training programs. Growth Horm IGF Res 2017, 32:33–40.
21.Li D, Misialek JR, Boerwinkle E, Gottesman RF, Sharrett AR, Mosley TH, Coresh J, Wruck LM, Knopman DS, Alonso A: Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study. Alzheimers Dement (Amst) 2016, 6:1–10.
22.Erickson KI, Prakash RS, Voss MW, Chaddock L, Hu L, Morris KS, White SM, Wójcicki TR, McAuley E, Kramer AF: Aerobic fitness is associated with hippocampal volume in elderly humans. Hippocampus 2009, 19(10):1030–1039.
23.Burns JM, Cronk BB, Anderson HS, Donnelly JE, Thomas GP, Harsha A, Brooks WM, Swerdlow RH: Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology 2008, 71(3):210–216.
24.Evans EM, Racette SB, Peterson LR, Villareal DT, Greiwe JS, Holloszy JO: Aerobic power and insulin action improve in response to endurance exercise training in healthy 77–87 yr olds. J Appl Physiol 2005, 98(1):40–45.
25.Lin F, Heffner KL, Ren P, Tivarus ME, Brasch J, Chen DG, Mapstone M, Porsteinsson AP, Tadin D: Cognitive and neural effects of vision-based speed-of-processing training in older adults with amnestic mild cognitive impairment: a pilot study. J Am Geriatr Soc 2016, 64(6):1293–1298.
26.Heinzel S, Lorenz RC, Brockhaus W-R, Wüstenberg T, Kathmann N, Heinz A, Rapp MA: Working memory load-dependent brain response predicts behavioral training gains in older adults. J Neurosci 2014, 34(4):1224–1233.
27.Mozolic JL, Hayasaka S, Laurienti PJ: A cognitive training intervention increases resting cerebral blood flow in healthy older adults. Front Hum Neurosci 2010, 4(16):1–10.
28.Takeuchi H, Taki Y, Hashizume H, Sassa Y, Nagase T, Nouchi R, Kawashima R: Effects of training of processing speed on neural systems. J Neurosci 2011, 31(34):12139–12148.
29.Yu F, Lin FV, Salisbury DL, Shah KN, Chow L, Vock D, Nelson NW, Porsteinsson AP, Jack C, Jr.: Efficacy and mechanisms of combined aerobic exercise and cognitive training in mild cognitive impairment: study protocol of the ACT trial. Trials 2018, 19(1):700.
30.Hakansson K, Ledreux A, Daffner K, Terjestam Y, Bergman P, Carlsson R, Kivipelto M, Winblad B, Granholm AC, Mohammed AK: BDNF responses in healthy older persons to 35 minutes of physical exercise, cognitive training, and mindfulness: associations with working memory function. J Alzheimers Dis 2017, 55(2):645–657.
31.Allard JS, Ntekim O, Johnson SP, Ngwa JS, Bond V, Pinder D, Gillum RF, Fungwe TV, Kwagyan J, Obisesan TO: APOEepsilon4 impacts up-regulation of brain-derived neurotrophic factor after a six-month stretch and aerobic exercise intervention in mild cognitively impaired elderly African Americans: A pilot study. Exp Gerontol 2017, 87(Pt A):129–136.
32.Szuhany KL, Bugatti M, Otto MW: A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. J Psychiatr Res 2015, 60:56–64.
33.Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel PP, Chang L, Rivnak AJ: Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010, 28(6):595–599.
34.Lachno DR, Emerson JK, Vanderstichele H, Gonzales C, Martenyi F, Konrad RJ, Talbot JA, Lowe SL, Oefinger PE, Dean RA: Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer’s disease therapeutics. J Alzheimers Dis 2012, 32(4):905–918.
35.Okereke OI, Xia W, Irizarry MC, Sun X, Qiu WQ, Fagan AM, Mehta PD, Hyman BT, Selkoe DJ, Grodstein F: Performance characteristics of plasma amyloid-β 40 and 42 assays. J Alzheimers Dis 2009, 16(2):277–285.
36.Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A et al: Plasma tau in Alzheimer disease. Neurology 2016, 87(17):1827–1835.
37.Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer’s Disease Neuroimaging I: Association of plasma neurofilament light with neurodegeneration in patients With Alzheimer’s disease. Jama Neurol 2017, 74(5):557–566.
38.Rubenstein R, Chang B, Yue JK, Chiu A, Winkler EA, Puccio AM, Diaz-Arrastia R, Yuh EL, Mukherjee P, Valadka AB: Comparing plasma phospho tau, total tau, and phospho tau–total tau ratio as acute and chronic traumatic brain injury biomarkers. Jama Neurol 2017, 74(9):1063–1072.
39.Cao J, Seegmiller J, Hanson NQ, Zaun C, Li D: A microfluidic multiplex proteomic immunoassay device for translational research. Clin Proteomics 2015, 12(1):28–33.
40.Li D, Chiu H, Chen J, Zhang H, Chan DW: Integrated analyses of proteins and their glycans in a magnetic bead–based multiplex assay format. Clin Chem 2013, 59(1):315–324.
41.Li D, Chiu H, Gupta V, Chan DW: Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta 2012, 413(19–20):1506–1511.
42.Li D, Misialek JR, Boerwinkle E, Gottesman RF, Sharrett AR, Mosley TH, Coresh J, Wruck LM, Knopman DS, Alonso A: Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst) 2016, 3:73–82.
43.Holm S: A simple sequentially rejective multiple test procedure. Scandinavian journal of statistics 1979, 6(2):65–70.
44.Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, Hill GB, McDowell I: Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002, 156(5):445–453.
45.Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM et al: Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A 2011, 108(7):3017–3022.